The Comparative Effectiveness of Enlonstobart and Camrelizumab as Second-Line Recurrent or Metastatic Cervical Cancer Therapies: Matching-Adjusted and Simulated Treatment Comparisons
This indirect comparison demonstrated that enlonstobart provided a significant OS advantage compared to camrelizumab in patients with second-line R/M CC. These findings suggest enlonstobart may represent a promising therapeutic option for PD-(L)1 positive R/M CC patients.
Authors
- Huiqiao Gu (ORCID: https://orcid.org/0009-0005-6250-4137)
- Y. Jiang
- Bingxin Hu
Institutions
- Sun Yat-sen University (CN)
- Shenzhen University (CN)
- Shenzhen University Health Science Center (CN)
Publication Details
- Journal
- ImmunoTargets and Therapy
- Published
- 2026-02-01
- DOI
- https://doi.org/10.2147/itt.s572970
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00